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Characterization of the human brain proteome is a critical area of research. While exam-
ination of the human cortex has provided some insight, very little is known about the pro-
teome of the human midbrain, which demonstrates substantial loss of dopaminergic neu-
rons in the substantia nigra pars compacta (SNpc) in Parkinson’s disease (PD). Therefore,
characterization of this region is essential to a better understanding of the pathogenesis of
PD. This dataset paper reports two separate studies, where human SNpc was collected from
PD and control subjects and 1263 proteins were identified using MALDI-TOF/TOF as well
as linear ion trap MS platforms. With gene ontology analysis, the proteins were categorized
according to their biological processes, as well as cellular components. These data were also
compared with previous proteomic characterization of the human frontal and temporal cor-
tex, and cerebrospinal fluid to establish shared proteins of relevance. The present dataset is
the most extensive survey of the human SNpc proteome, to date. Further characterization of
the SNpc proteome will significantly facilitate our understanding of the function and
expression of proteins involved in PD, as well as provide potential proteins that may be
utilized as biomarkers.
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Since the completion of the human genome project, it
has become clear that characterization of the human pro-
teome is indispensable to our understanding of the biologi-
cal function and processes of proteins, both in a normal as
well as a pathological state. Recently, we, as well as others,
have begun to identify proteins that are unique to certain
brain regions in order to characterize proteins that may qua-
litatively change under pathological conditions [1–3]. For
example, proteomic analysis of human frontal cortex that is
typically involved in cognitive function and geriatric demen-
tia (using a platform of biochemical fractionation, multi-
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dimensional LC separation, and a MALDI-TOF/TOF mass
spectrometer) identified over 800 proteins, of which several
were found to be associated with neurodegenerative disease
[1]. Furthermore, examination of the human temporal lobe, a
region often involved in epilepsy (using 2-DE separation with
MALDI-TOF/TOF [4] as well as a shotgun proteomics
approach that utilized strong cation exchange (SCX), RP-LC
and 3-D ion trap mass spectrometry [5]) has identified several
hundred proteins, including many linked to epilepsy.
The focus of this dataset paper is the midbrain whose
degeneration is linked to multiple movement disorders,
including Parkinson’s disease (PD), multiple system atrophy,
and progressive supranuclear palsy. The human midbrain is
composed of several different regions, including the superior
and inferior colliculi, red nucleus, substantia nigra pars reti-
culata, ventral tegmental area (VTA), and substantina nigra
pars compacta (SNpc). It is the degeneration of dopamine-
containing neurons in the SNpc that underlies the motor
deficits that characterize most movement disorders [6]. In an
earlier study of human midbrain we utilized isotope coded
affinity tag (ICAT) labeling of mitochondrial-enriched pro-
teins from the SNpc of human PD and control brains, fol-
lowed by analysis with linear ion trap MS (LTQ) [7]. Com-
parison of the protein profiles in the SNpc of PD patients
with those of age-matched controls identified 842 proteins, of
which 119 proteins displayed changes in relative abundance
in the diseased tissue vs. controls [7]. These data are a much
larger representation of the SNpc proteome than has been
previously demonstrated in other studies. For example,
examination of SNpc of human PD and control samples
through 2-DE identified 44 proteins, of which nine showed
changes in expression between control and disease brains [8].
As a part of an ongoing effort to further characterize
and understand the human midbrain proteome as well as
identify alterations in protein expression levels in a normal
and pathological state, we have recently compared the pro-
teome of the SNpc with another midbrain region, the VTA
that is much less sensitive to neurodegeneration in PD.
While proteins displaying quantitative changes are being
evaluated extensively (and will be published separately), the
results on protein identification in the midbrain is reported
here, along with proteins identified previously by us [7] after
standardization of the data processing. We hope that mak-
ing these data available to other investigators in the field can
facilitate the process of characterization of the human mid-
brain, comprehensively. To make our dataset even more
user-friendly, we will make it publicly accessible on our
website as well as the PRIDE database managed by the Eu-
ropean Bioinformatics Institute (EBI). Finally, we hope that
this dataset will contribute to the current initiatives that are
supported by the National Institutes of Health (Brain Mo-
lecular Anatomy project: http://trans.nih.gov/bmap/) as
well as the Human Proteome Organization (www.hupo.
org).
Technical details are provided for three major aspects of
the investigation:
(i) Sample preparation: Samples from SNpc and VTA of
human midbrain were obtained at autopsy according to pro-
tocols approved by the University of Washington School of
Medicine, Mayo Clinic in Florida, University of Michigan,
and Emory University. The average age of the subjects was
76 years old and postmortem interval was less than 12 h. All
control subjects (four males and one female; average age:
82 years) were individuals who were not diagnosed with a
neurological disease and whose neuropathological examina-
tion revealed age-related changes only. All PD patients (five
males of an average age of 70 years) had been clinically
diagnosed with an extrapyramidal movement disorder or
dementia, and their final diagnoses were established by
neuropathological examination according to established cri-
teria [9, 10]. Four groups of samples were analyzed: Control
VTA (n = 5), Control SNpc (n = 5), PD VTA (n = 5), and PD
SNpc (n = 5).
Frozen samples were rapidly thawed in ice-cold homog-
enization buffer (0.32 M sucrose, 20 mM HEPES, pH 7.5,
1 mM PMSF, phosphatase inhibitors (0.2 mM Na3VO4 and
1 mM NaF) and protease inhibitor cocktail from Sigma, St.
Louis, MO), and then disrupted with a glass-Teflon homo-
genizer (Wheaton, Millville, NJ) by ten gentle up and down
strokes. The protein concentrations of the homogenates were
determined using a Pierce BCA Protein Assay kit (Rockford,
IL). Equal amount of proteins from five individual samples
in each group were combined together. Cytosolic, mitochon-
drial and nuclear fractions of SNpc were prepared as pre-
viously described [1]. Fractionation of tissue was not
designed to achieve pure sub-cellular organelles, as this is
not practically possible for frozen human brain. Rather, this
procedure was instituted for deeper probing of the human
proteome.
(ii) Protein identification and quantification: For pro-
teins in each of the enriched fractions in the four groups, i.e.
control VTA, control SNpc, PD VTA, and PD SNpc, this was
achieved using the iTRAQ labeling technique that is routi-
nely utilized in our lab [11]. In this study, for each enriched
fraction, 100 mg of proteins from each group were tryptically
digested in parallel and then labeled with iTRAQ reagents
(Applied Biosystem, Foster City, CA) according to the manu-
facture’s protocol. The labeled digests from the four groups
were combined together and further separated into nine
fractions using an offline SCX PolySulfoethyl ATM column
(200 mm62.1 mm id, 5 micron, 300 Å, Poly LC, Columbia,
MD). Of note again, results related to quantitative changes
among different regions and/or disease vs. controls will be
reported separately.
Each SCX fraction was collected and further separated by
RP nanocapillary LC (LC Packing/Dionex, Sunnyvale, CA).
The mass spectrometric analysis was carried out using a
MALDI-TOF/TOF instrument (4700 Proteomics Analyzer,
Applied Biosystems) with reflector positive ion mode and
each fraction was analyzed in triplicate. Spectral results were
searched against the International Protein Index (IPI) hu-
man protein database (version 3.18) from the EBI using the
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GPS software (version 3.6, Applied Biosystems) running
MASCOT search algorithm (version 2.0, Matrix Science,
Boston, MA) for peptide and protein identification. All pro-
teins identified by a decoy database (less than 2% of total
proteins) were eliminated from the list of proteins reported.
It should be noted that the data related to ICAT and LTQ
analysis of SNpc has been reported previously as an appendix
associated with a biology paper [7]. A few key elements are
repeated here for the readers’ reference and standardization
of the dataset. Briefly, proteins were identified in the SNpc of
control and PD patients using the ICAT labeling technique,
initially described by Gygi et al., [12] and routinely used in
our lab [1, 3, 13]. For the LTQ platform, peptides were sepa-
rated and analyzed on an LTQ work station (Thermo Elec-
tron, San Jose, CA) using automated, on-line 2-D LC separa-
tion followed by nanoelectrospray LC/MS [14]. Proteins from
the mixture were later identified automatically using the
computer program SEQUEST, which searched the MS/MS
spectra against the human IPI database (version 2.33 in
initial publication, but reprocessed with version 3.18) data-
base [3, 13]. Potential peptides and proteins were further an-
alyzed with two newly developed computer software pro-
grams, PeptideProphet and ProteinProphet based on statis-
tical models [15]. The list of proteins filtered by
ProteinProphet typically has very little overlap (less than 1%)
with that searched with a decoy database [16].
(iii) Bioinformatics: The Gene Ontology (GO) analysis
was carried out at the Bioinformatics and Biostatistics Facil-
ity Core of the University of Washington. All proteins identi-
fied were analyzed by GO for protein categorization [17].
Briefly, queries using the IPI values were submitted to the
EMBL-EBI IPI database using the Bioconductor [18] software
package. Bioconductor commands were used to construct
and send dbfetch queries to the IPI database via a URL, for
example, http://www.ebi.ac.uk/cgi-bin/dbfetch?db=IPI$id=
IPI00298853. These IPI query results were further processed
in Bioconductor to construct a master table containing IPIs,
Entrez Gene IDs, Gene Symbols, and Gene Descriptions.
The Entrez Gene IDs were used in conjunction with the
Bioconductor biomart package [19] to query the Ensembl
BioMart database for the GO IDs as well as GO categories of
the three GOs (Biological Process, Molecular Function, Cel-
lular Component). Because any Entrez Gene ID can occur in
more than one GO category, the calculation of the numbers
of proteins in selected GO categories, whether cellular com-
ponent or biological process, was done on a priority basis,
meaning that a gene/protein was removed from the master
table after it was classified so that multiple counting of the
gene/proteins was avoided.
As mentioned previously, the proteins identified in the
SNpc in our investigations are the most extensive thus far. A
few key technical and biological issues unique to this dataset
are discussed further as the following:
(i) Protein identification and GO analysis: All current
MS-based proteomics is biased towards identification of pro-
teins of high abundance [20] thus, it is critical to fractionate
tissue homogenates to achieve a deeper analysis of the cel-
lular proteome. Moreover, through this approach, it is more
likely to identify the proteins whose total cellular levels
remain the same but relative levels in specific cellular com-
partments change during processes. For example, in our
previous ICAT analysis of PD SNpc versus control SNpc,
mortalin was found to be decreased in mitochondrial but not
cytosolic fractions, a fact further validated by alternative
means [7]. Our current study led to the identification of 951
proteins; of those, 399 non-redundant proteins were identi-
fied with two or more peptides. The number of non-redun-
dant proteins identified with two or more peptides was 313,
114, and 170 for cytosolic, mitochondrial, and nuclear frac-
tions, respectively (a total of 399 after removing redundant
proteins). A second set of proteins was identified using a
multidimensional separation strategy in combination with
Figure 1. Overlap of the SNpc proteome with the Temporal Lobe
(A), Frontal Cortex (B), and CSF (C). Only proteins identified by
two or more peptides were included in these comparisons.
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an ESI based ion trap mass spectrometer [7, 21]. Using this
approach, 1049 proteins were identified by at least two pep-
tides. It should be noted that previous analysis of this same
dataset yielded 842 proteins identified by two or more pep-
tides. This discrepancy in the number of proteins identified
can be attributed to the rapid progression of the proteomics
field and the updating of the protein database that was origi-
nally used. Indeed, our previous investigation has indicated
that a significant number of proteins are altered when an
identical MS data was searched against two different ver-
sions of the IPI database [11].
When MALDI-TOF/TOF protein identification was com-
bined with the LTQ study [7] a total of 1263 non-redundant
proteins were identified in the SNpc, which represents the
most extensive characterization of the human midbrain to
date. Notably, 14 proteins identified previously by a single
peptide were seen in the current study with more than two
peptides. Conversely, 87 proteins identified in the current
study by a single peptide were revealed in the previous
investigation by more than two peptides. Nonetheless, to
comply with the general rule of proteomic data depository,
only proteins identified by more than two peptides in at least
one study are reported here. A complete list of the proteins
can be found in Supporting Information Table 1.
SNpc proteins identified by more than two peptides in
our study were classified in accordance with their distribu-
tion into cellular components and biological processes based
on GO analysis and annotations (Supporting Information
Fig. 1). Categorization of proteins provides a starting point,
from which a more in-depth investigation of individual pro-
teins that show potential involvement in PD can be under-
taken. The major cellular components of the proteins identi-
fied fall into several categories, including mitochondria,
membrane and endoplasmic reticulum/lysosome, and
nuclear (Supporting Information Fig. 1A). The main biolog-
ical functions of the proteins identified in the SNpc include
oxidative stress processes, regulation of cytoskeletal organi-
zation, as well as participation in cell–cell communication
and signaling (Supporting Information Fig. 1B). A signifi-
cant portion of proteins have various other functions that
collectively fall into a category denoted as “others”. With the
advance of bioinformatics and proteomics technology, it is
hoped that a complete characterization of the midbrain pro-
teome will be achieved in the years to come.
(ii) Comparison of the SNpc proteome with other hu-
man brain regions and CSF as well as mouse midbrain: Of
the 1263 proteins identified in midbrain, 534 have been
reported previously in the temporal cortex [24] and 350 in the
frontal cortex [1]. The overlap of the proteins identified in
each of the proteomes is demonstrated in Fig. 1A and B,
respectively. We have also compared our current SNpc data-
set with a previous proteomic study that utilized 2-DE and
MALDI-TOF-MS to identify 44 proteins in human SNpc [8].
Of these 44 proteins, over 75% of them were also identified
in our study, providing evidence for the validity of our
results. In addition, comparison of proteins recently identi-
fied by our lab in a proteomic study of mouse midbrain
determined overlap between numerous proteins found in
both human SNpc and mouse midbrain [3]. Examples of
some of these proteins include, HSPs, 14-3-3, thioredoxin,
glutathione S-transferase, and ubiquitin carboxy-terminal
hydrolase L1 (UCHL-1). These data provide further evidence
for the utility of using mice as a reliable model of PD. On the
other hand, a significant portion of proteins (over 99%)
identified in human SNpc were not identified in a mouse
genomic comparison between the SNpc and VTA [23]
emphasizing again that it is imperative to investigate the
human CNS proteome (ideally human) directly.
Finally, we compared the proteins identified in the mid-
brain with those in human cerebrospinal fluid (CSF). CSF is
easily accessible and the proteins present in it could be used
as biomarkers for neurodegenerative diseases. Furthermore,
CSF is a viable source for biomarker discovery because of its
proximity to the site of pathology and because it reflects the
metabolic state of the brain under varying conditions that
effect protein concentrations and patterns in CSF con-
siderably. By comparing the previously identified CSF pro-
teome (a total of 2556 proteins) [2, 11] with that of the SNpc
identified in our present study, 198 proteins were found to be
shared by the SNpc and CSF proteomes (Fig. 1C). Many of
these shared proteins, e.g. calmodulin, g-enolase, and myelin
basic protein are known to be involved in a variety of CNS
functions. While these data represent the most current eval-
uation of the human SNpc available, we realize that the dy-
namic and continually progressing nature of proteomic
technology may further validate or abrogate these findings.
(iii) Discussion of the proteins identified in the dataset:
Among the proteins identified in the SNpc tissue, many of
them are functionally or structurally involved in neurode-
generation. Further characterization of these proteins will
facilitate a more complete understanding of the pathogen-
esis of various movement disorders. Proteins that are well
known to be critical to movement disorders are listed in
Supporting Information Table 2. A significant number of
these proteins are involved in the process of mitochondrial
function, oxidative stress, protein degradation, and neuroin-
flammation, processes that have been clearly indicated to be
important to neurodegenerative diseases, including PD (e.g.
DJ-1, glutathione S-transferase omega1, manganese super-
oxide dismutase, and UCHL-1). These proteins have been
discussed extensively in the literature. Additionally, as one of
the most important advantages of nonbiased proteomics
centers on discovering novel proteins that are yet to be
determined to be critical to a particular disease or disease
state, we have decided to focus the remainder of the discus-
sion on a subset of proteins that have not been related to PD
pathogenesis thus far, although investigations in other fields
appear to suggest their roles in neural functions.
Calbindin: Calbindin D28K protein is a calcium binding
protein [24] involved in the regulation of intracellular cal-
cium [25]. Calbindin is expressed in dopamine neurons of
the dorsal tier of the SNpc that project to the limbic region of
© 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.clinical.proteomics-journal.com
780 E. Kitsou et al. Proteomics Clin. Appl. 2008, 2, 776–782
the telencephalon and cerebral cortex [26]. In contrast, dop-
amine neurons from the ventral tiers of the SNpc do not
contain calbindin and project to the dorsolateral motor puta-
men [27]. Interestingly, dopamine neurons located in the
VTA also express calbindin [28] yet seem to be less vulnerable
to PD than dopamine neurons in the SNpc [29]. Further-
more, Calbindin does not appear to demonstrate a neuro-
protective role [30] which suggests that other cellular char-
acteristics are involved in mediating the differential vulner-
ability of dopamine neurons in the VTA and SNpc.
Calmodulin: Calmodulin is a calcium binding protein
that binds and modulates several different cellular processes,
including inflammation, metabolism, and apoptosis. Our
study identified six peptides associated with calmodulin. Of
these, two peptides (91-106, 127-148) cover the calcium-
binding regions. A recent study showed that calmodulin
binds to a-synuclein in a calcium dependent-manner and
accelerates a-synuclein fibrillation [31] which has been
demonstrated to be a major factor in the pathogenesis of PD.
In addition, oxidative stress and mitochondrial dysfunction
have been suggested to be involved in the pathogenesis of
neurodegenerative diseases, and calmodulin has been linked
to both these processes [32]. Finally, a comparative proteomic
analysis of striatum from rats exposed to 6-hydroxy-dopa-
mine identified calmodulin as a protein that underwent a
change in expression in rats treated with 6-hydroxy-dop-
amine, compared with control [33].
Cofilin: This protein belongs to the protein family of
ADF/cofilins [34] and is an important regulator of actin, a
key component of microtubules [35]. Disruption of micro-
tubules and subsequent axonal transport could have detri-
mental effects on numerous cellular processes integral to
the well-being of the cell. Cofilin has been implicated initi-
ally in Alzheimer’s disease [36] and it is suggested that
neurodegenerative stimuli can activate ADF/cofilin by
dephosphorylation, causing the formation of bars which can
impair axonal transport along the microtubules, inhibiting
neurite function [37]. There is also data showing that 1-
methyl 4-phenyl 1,2,3,6-tetrahydropyridine (MPTP) treated
mice demonstrate changes in the expression of the cyto-
skeletal genes, including cofilin [38]. Furthermore, parkin, a
protein that has been implicated in inherited forms of PD,
may interact with LIM kinase-1 and suppress the phospho-
rylation of cofilin [39].
14-3-3: 14-3-3 proteins, a family of chaperones that parti-
cipate in many signaling pathways, are abundant in the
brain. In this study, six different isoforms of 14-3-3 protein
were identified in the SNpc, including beta/alpha, epsilon,
eta, gamma, theta, and zeta/delta. There is evidence sug-
gesting that 14-3-3 proteins may play a central role in PD
pathogenesis [40] as it has been shown by immunochemical
studies to colocalize with Lewy bodies [41]. In addition, it has
been shown that one family member, 14-3-3 eta specifically
interacts with parkin and inhibits its ubiquitin ligase activity,
which could impede proteasomal degradation of damaged or
misfolded proteins in the cell [42].
Stathmin: Stathmin is a cytosolic phosphoprotein,
abundantly expressed in human brain, playing a role in adult
neurogenesis [43]. Stathmin regulates microtubule dynam-
ics [44] and by way of this function it has been suggested by
in vitro studies that when overexpressed it could lead to Golgi
fragmentation – a process that links stathmin to amyo-
trophic lateral sclerosis [45]. In addition, stathmin has been
associated with Alzheimer’s disease and Down’s syndrome
[46] therefore it could have a role in other neurodegenerative
diseases such as PD for which Golgi fragmentation could be
a contributing factor in the pathogenesis of neuronal degen-
eration [47]. Interestingly, a recent study demonstrated Golgi
fragmentation in the SNpc of PD patients exhibiting a-
synuclein positive inclusions [48].
g-Synuclein: One of the three members of the human
synuclein family, including a, b-synuclein, g-synuclein
shows 60% similarity with a-synuclein at the amino acid
sequence level [49] and is expressed throughout the brain,
particularly in the substantia nigra [50]. In contrast to a-
synuclein, which has been extensively demonstrated to be
involved in the pathogenesis of PD, the role of g-synuclein in
PD is still disputable. Although studies have demonstrated a
lack of specific polymorphisms in the g-synuclein gene, sev-
eral studies have shown potential aggregations of g-synu-
clein in neuronal structures [51]. More recently, it has been
shown that g-synuclein is able to inhibit a-synuclein fibrilla-
tion, a potentially imperative step in a-synuclein-mediated
PD pathology [52].
In summary, our work provides an inventory of proteins
that are linked to neurodegenerative processes. The expres-
sed proteins need to be validated and more thoroughly
characterized to elucidate their function. It is important to
recognize that the SNpc is not a homogeneous structure. In
primates, the dopaminergic SNpc neurons are inter-
digitated with GABAergic substantia nigra pars reticulata
neurons. Within the SNpc, some groups of dopaminergic
neurons are more affected than others by whatever pro-
cesses cause neurodegeneration in PD [53]. In the future,
more fine grained analyses will be needed to assess protein
changes in subpopulations of SNpc neurons. Given the
complexity of proteomic research and the limited access to
brain tissue from patients and healthy individuals this pre-
liminary protein database of the human SNpc could be the
first step towards early diagnosis and development of ther-
apeutic targets. Additionally, proteins present in both tissue
and CSF may provide tissue specific markers for PD diag-
nosis and progression.
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